Contributions
Abstract: PB2122
Type: Publication Only
Background
Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant abnormality of plasma cells, with increased serum levels of immunoglobulins. Patients with MGUS may evolve to multiple myeloma (MM) through a multistep process, including also deregulation of gene expression.
Aims
We aimed to demonstrate that MGUS patients display a deregulation of miRNA gene expression (short non-coding RNAs, regulating gene expression at the translational level) in peripheral lymphomonocytes.
Methods
Utilizing reverse transcription quantitative polymerase chain reaction we independently measured MiRNome expression profile in healthy and MGUS subjects.
Results
We obtained a specific MGUS microRNAs signature. Furthermore, six different pathways involved in important cellular processes of lymphomonocytes were analysed using in silico analysis, in order to identify dysregulated miRNAs in MGUS compared to controls. IL6 pathway, intrinsic and extrinsic apoptosis pathways, G1/S transition of the cell cycle, AKT-dependent pathway and PI3K pathway were influenced by 141 dysregulated miRNAs, making lymphomonocytes anti-apoptotic, non-proliferative, metabolically altered and inhibiting activation of angiogenic and immune responses.
Conclusion
This study demonstrates that MGUS patients have a different microRNA profile in peripheral blood cells in comparison with healthy donors, and that these microRNAs may play a role in the immune response and in anti-apoptotic processes.
Session topic: 13. Myeloma and other monoclonal gammopathies – Biology & Translational Research
Keyword(s): Genetic modifiers, Lymphocyte, MGUS
Abstract: PB2122
Type: Publication Only
Background
Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant abnormality of plasma cells, with increased serum levels of immunoglobulins. Patients with MGUS may evolve to multiple myeloma (MM) through a multistep process, including also deregulation of gene expression.
Aims
We aimed to demonstrate that MGUS patients display a deregulation of miRNA gene expression (short non-coding RNAs, regulating gene expression at the translational level) in peripheral lymphomonocytes.
Methods
Utilizing reverse transcription quantitative polymerase chain reaction we independently measured MiRNome expression profile in healthy and MGUS subjects.
Results
We obtained a specific MGUS microRNAs signature. Furthermore, six different pathways involved in important cellular processes of lymphomonocytes were analysed using in silico analysis, in order to identify dysregulated miRNAs in MGUS compared to controls. IL6 pathway, intrinsic and extrinsic apoptosis pathways, G1/S transition of the cell cycle, AKT-dependent pathway and PI3K pathway were influenced by 141 dysregulated miRNAs, making lymphomonocytes anti-apoptotic, non-proliferative, metabolically altered and inhibiting activation of angiogenic and immune responses.
Conclusion
This study demonstrates that MGUS patients have a different microRNA profile in peripheral blood cells in comparison with healthy donors, and that these microRNAs may play a role in the immune response and in anti-apoptotic processes.
Session topic: 13. Myeloma and other monoclonal gammopathies – Biology & Translational Research
Keyword(s): Genetic modifiers, Lymphocyte, MGUS